Director Brian Thomas resigns from Metagenomi board; shareholders re-elect Eckhardt, Bjerkholt and ratify PwC as auditor

Metagenomi Therapeutics, Inc.

Brian C. Thomas, Ph.D. resigned from the board effective June 9, 2026, with no disagreement with the company.
Juergen Eckhardt and Eric Bjerkholt elected as Class II directors to serve until 2029 annual meeting.
PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year 2026 with 18,483,295 votes for, 51,847 against.
Quorum of 19,116,207 shares present out of 37,647,057 outstanding at the June 9, 2026 annual meeting.

item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brian C. Thomas

Director

MGX · Metagenomi Therapeutics, Inc.

Effective: 2026-06-09
Filed: June 9, 2026, 6:11 PM ET

On June 9, 2026, Brian C. Thomas, Ph.D. informed the board of directors (the “Board”) of Metagenomi Therapeutics, Inc. (the “Company”) of his resignation from his position as a member of the Board, effective as of June 9, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian C. Thomas resigned as director at Metagenomi Therapeutics, Inc..

Action: resigned

Exact text from the filing

On June 9, 2026, Brian C. Thomas, Ph.D. informed the board of directors (the “Board”) of Metagenomi Therapeutics, Inc. (the “Company”) of his resignation from his position as a member of the Board, effective as of June 9, 2026.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Metagenomi Therapeutics, Inc. shareholders approved Election of Juergen Eckhardt, M.D., M.B.A. and Eric Bjerkholt, M.B.A. as Class II Directors at the 2026-06-09 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-09

Exact text from the filing

Proposal 1 - Juergen Eckhardt, M.D., M.B.A. and Eric Bjerkholt, M.B.A. were elected as Class II Directors to serve until the Company’s 2029 annual meeting of stockholders, and until their respective successor shall have been duly elected and qualified, or until their earlier death, resignation or removal, based on the following votes: Class II Director Nominee For Withheld Broker Non-Votes Juergen Eckhardt, M.D., M.B.A. 7,296,718 1,436,882 10,382,607 Eric Bjerkholt, M.B.A. 8,251,289 482,311 10,382,607

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Metagenomi Therapeutics, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-09

Exact text from the filing

Proposal 2 – The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, based on the following votes: For Against Abstentions 18,483,295 51,847 581,065

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Metagenomi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-264392

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.